Escitalopram (ESC) is considered one of the most effective selective serotonin reuptake inhibitors (SSRI) for the treatment of major depression disorder. However, little is known on its potential risk of inducing major malformations (MM) and/or perinatal complications (PC). Aim of the present study is to provide a review of the available literature on the safety profile of ESC during pregnancy and breastfeeding and to compare data with the maternal and neonatal outcomes of 8 cases of the DEGRA Center.
[The safety profile of escitalopram in pregnancy and breastfeeding] / Bellantuono, Cesario; Orsolini, Laura; Bozzi, Francesca. - In: RIVISTA DI PSICHIATRIA. - ISSN 0035-6484. - 48:6(2013), pp. 407-414. [10.1708/1379.15335]
[The safety profile of escitalopram in pregnancy and breastfeeding]
Bellantuono, Cesario;Orsolini, Laura;Bozzi, Francesca
2013-01-01
Abstract
Escitalopram (ESC) is considered one of the most effective selective serotonin reuptake inhibitors (SSRI) for the treatment of major depression disorder. However, little is known on its potential risk of inducing major malformations (MM) and/or perinatal complications (PC). Aim of the present study is to provide a review of the available literature on the safety profile of ESC during pregnancy and breastfeeding and to compare data with the maternal and neonatal outcomes of 8 cases of the DEGRA Center.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
